Cholesterol and statins are among the most extensively researched topics in clinical medicine, but controversy continues to rage over how to interpret this vast and growing body of evidence and translate it into better clinical care for patients. In 2013, after a 9-year hiatus, guidelines for treatment of high cholesterol were updated by the American College of Cardiology and the American Heart Association.1 The new guidelines shifted treatment recommendations in several important ways, perhaps the most important of which was to recommend that statin primary prevention treatment decisions be made nearly entirely on the basis of a patient’s overall risk for atherosclerotic cardiovascular disease instead of accounting for the low-density lipoprotein cholesterol (LDL) level (unless LDL is extremely elevated). This increasing emphasis on risk-based statin prescribing strikingly demotes LDL levels in importance compared with previous guidelines, shifts prescribing towards older men who are at higher average short-term risk,2 and has elicited controversy.3

In this issue of EBM, Sauser and colleagues review the evidence for LDL-lowering treatment of patients with an elevated level of LDL cholesterol but relatively low short-term (10-year) cardiovascular risk.4 The basic rationale for the ‘early LDL treatment hypothesis’ is that high-LDL cholesterol causes cumulative damage to coronary arteries (in the form of atherosclerosis) even during young adulthood when risk of cardiovascular events is low, and that early LDL-lowering could reduce that damage accumulation and thereby reduce coronary heart disease risk in the long term more than waiting to treat LDL cholesterol until later in life when event risk becomes higher. To assess the evidence for this early LDL treatment hypothesis, the authors conducted an extensive review of randomised controlled trials of LDL-lowering and patient outcomes and longitudinal observational studies including Mendelian randomisation studies, and solicited additional specific arguments and sources of evidence from established experts.

After excluding arguments based on pathophysiology, the authors identified three fundamental arguments supporting the early LDL treatment hypothesis and focused their evidence review accordingly. These arguments are: (1) that patients at lower cardiovascular risk get more benefit per amount of LDL reduction; (2) that statin trials demonstrate a ‘legacy effect’ whereby cardiovascular risk of treated patients continues to be reduced even after the trial ends; and (3) that Mendelian randomisation studies demonstrate that lifelong LDL-lowering from genetic factors produces a much larger relative risk reduction than seen in statin trials. The authors found support for arguments 1 and 3, no support for 2 (though they did not consider an oft-cited legacy effect trial5), provide methodological critiques and alternative explanations for the supporting evidence, and point out a critical gap in the evidence: that there is no clinical study (certainly no randomised controlled trial) demonstrating that LDL-lowering with a statin early in life, when cardiovascular risk is low, is actually superior in terms of reducing clinical events than waiting to start statin therapy until cardiovascular risk is elevated (eg, 10-year risk >7.5%).

This last point is irrefutably true. The only direct way to demonstrate that early LDL treatment would reduce cardiovascular events more than ‘late’ treatment (waiting until risk is elevated) would be to randomly assign patients with elevated LDL but low risk to immediate versus delayed (risk-based) statin therapy, and then follow those persons through many decades of life to see if cardiovascular events are reduced later in life by early treatment. The length of follow-up alone (essential to the design) and inevitable resulting challenges with engagement and compliance over that long follow-up in the context of a rapidly changing landscape (new drugs, new ways to predict risk), as well as the likely immense cost of such a study, make it quite unlikely that any such trial will ever be conducted. One reasonable answer to the question posed by this review, therefore, is something of a forgone conclusion: that there is ‘no clinical evidence for or against whether starting before 10-year risk is 7.5–12.5% provides substantial additional net patient benefit’.

In the absence of that direct clinical evidence, we must do our best to glean indirect evidence to inform this critical clinical question. Sauser and colleagues add substantially to this debate by their creative reframing of arguments, careful literature review and intelligent discussion of flaws in the attempts of others to use indirect evidence to support the early LDL treatment hypothesis. These flaws should certainly mitigate the enthusiasm of early LDL treatment hypothesis advocates.

It is unclear, however, why pathophysiological arguments, which were excluded from consideration by the authors, should be irrelevant to this evidence review. Atherosclerosis is the unquestioned primary intermediary between cardiovascular risk factors such as LDL cholesterol and clinical cardiovascular events (though there are others, such as inflammation and thrombosis). Large and well-designed observational studies have demonstrated clear associations between cardiovascular risk factors and atherosclerosis early in life,5–9 persistence of atherosclerosis from early in life into later life10 11 and between atherosclerosis and clinical events;12 and a randomised trial has shown that statin treatment early in life reduces atherosclerosis.13 Recent evidence, cited in this review, demonstrates that cumulative exposure to hyperlipidaemia during young adulthood is an independent risk factor for cardiovascular events later in life.14 While this evidence also has flaws (some pointed out by Sauser et al), it supports the
pathophysiological argument and indirect evidence for early LDL treatment.

Additional evidence has recently accumulated on another related aspect of the guidelines—whether to treat an LDL target. Recent randomised controlled trials demonstrate that newer non-statin medications, when used in conjunction with statins to drastically reduce LDL levels, appear to reduce clinical events in high-risk patients.\textsuperscript{15–17} The decision to initiate LDL-lowering therapy with a statin in a low-risk patient is not the same as the decision to intensify LDL-lowering treatment in a high-risk patient, and this new evidence does not mean ezetimibe and PCSK9 inhibitors should have a place in current guidelines, but it does seem to add weight to the argument that LDL levels matter.\textsuperscript{18}

Comparing cholesterol guidelines to blood pressure guidelines provides an interesting perspective. As for cholesterol, only indirect evidence supports lowering blood pressure during early adulthood when overall cardiovascular risk is low. However, in spite of similarities in the evidence profile, blood pressure guidelines clearly recommend treatment based on a high level of the risk factor without consideration for cardiovascular risk.\textsuperscript{19} There are undeniable differences in the evidence base for these two risk factors, but the clear discrepancy in this specific ‘early treatment’ aspect of the recommendations raises questions about whether historical considerations or other non-evidence-based factors may be influencing the decisions of these parallel guideline committees as they interpret the evidence base.

As experts continue to debate the strength of the indirect evidence supporting the early LDL treatment hypothesis, clinicians must make real-world decisions about treating their patients with elevated LDL cholesterol and low short-term risk. Just as the guideline authors hedged their bets by recommending statins when LDL is over 190 mg/dL, clinicians can hedge their bets for patients by taking degree of LDL elevation into account, and there is little evidence supporting the rather arbitrary 190 mg/dL threshold. As clinicians decide how high is too high for any particular patient, they are well-justified in using all possible sources of information to make their best guess about what is right for their patients. This should clearly include patient preference about statin use, as antipathy to taking a pill every day and concerns about adverse effects can easily overwhelm the small average absolute benefits of statin therapy.\textsuperscript{20} It might include weighing the cost of statin therapy obtainable by the patient,\textsuperscript{21} though such utilitarian reasoning can feel repugnant to clinicians and patients. It might even make sense to perform additional testing for atherosclerosis, such as with CT-enabled quantification of coronary calcium,\textsuperscript{22} or genetic markers of risk for cardiovascular disease or statin effectiveness.\textsuperscript{23} All things considered (and we must consider all things when making decisions at the limits of EBM), the decision to start statins in the context of high cholesterol and low short-term risk remains a difficult one for patients and clinicians. Though the definitive trial may not be feasible, anything we can do to generate more indirect evidence, such as opening access to statin trial data currently maintained by the Cholesterol Treatment Trialists group to more researchers (as called for by Sauser and colleagues) and generating additional knowledge relevant to the decision (such as long-term statin safety data) will certainly be welcome.


Competing interests None declared.

Provenance and peer review Commissioned; internally peer reviewed.

References


